Related Experiment Videos

The intuitive case for β-blockers in patients with ESRD

Rory F McQuillan, Christopher T Chan

    Seminars in Dialysis
    |January 26, 2012
    PubMed

    Insights

    Sudden cardiac death (SCD) is a major concern for dialysis patients. Beta-blockers may help prevent SCD in this population, despite challenges in their use.

    Area of Science:

    • Nephrology and Cardiology
    • Cardiovascular Research

    Background:

    • Sudden cardiac death (SCD) accounts for up to 25% of mortality in dialysis patients.
    • Unlike the general population, coronary artery disease is less frequently the cause of SCD in dialysis patients.
    • Sympathetic nervous system activation is common in dialysis patients and may contribute to SCD.

    Discussion:

    • Beta-blockers are effective in reducing SCD in the general population.
    • Their mechanism of action suggests potential efficacy in preventing SCD in dialysis patients.
    • This review examines the evidence for beta-blocker use in end-stage renal disease (ESRD).

    Key Insights:

    • The etiology of SCD in dialysis patients differs from the general population.
    • Beta-blockers represent a potential therapeutic strategy for reducing SCD in this high-risk group.
    • Evidence supporting beta-blocker use in ESRD requires careful consideration.

    Outlook:

    • Further research is needed to overcome impediments to beta-blocker use in dialysis patients.
    • Future clinical trials should focus on optimizing beta-blocker therapy for SCD prevention in ESRD.
    • Understanding the specific challenges and benefits is crucial for clinical practice.

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...